SG Americas Securities LLC Buys 6,195 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

SG Americas Securities LLC grew its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 128.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,003 shares of the company’s stock after acquiring an additional 6,195 shares during the quarter. SG Americas Securities LLC’s holdings in Denali Therapeutics were worth $224,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Creative Planning increased its stake in Denali Therapeutics by 8.7% in the second quarter. Creative Planning now owns 43,033 shares of the company’s stock valued at $999,000 after purchasing an additional 3,458 shares in the last quarter. CWM LLC grew its holdings in shares of Denali Therapeutics by 43.6% in the 3rd quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after buying an additional 654 shares during the period. nVerses Capital LLC bought a new stake in shares of Denali Therapeutics in the 3rd quarter valued at $288,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Denali Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after buying an additional 920 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Denali Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 27,535 shares of the company’s stock worth $802,000 after acquiring an additional 10,782 shares in the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Denali Therapeutics news, Director Vicki L. Sato sold 3,080 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total value of $64,402.80. Following the transaction, the director now directly owns 107,976 shares in the company, valued at $2,257,778.16. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Ryan J. Watts sold 29,266 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $591,758.52. Following the completion of the transaction, the chief executive officer now directly owns 260,721 shares in the company, valued at $5,271,778.62. The trade was a 10.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 47,940 shares of company stock valued at $973,442. 7.90% of the stock is currently owned by corporate insiders.

Denali Therapeutics Price Performance

Denali Therapeutics stock opened at $22.25 on Friday. The company has a market cap of $3.20 billion, a price-to-earnings ratio of -8.06 and a beta of 1.43. The firm has a 50-day moving average of $22.25 and a 200-day moving average of $24.83. Denali Therapeutics Inc. has a one year low of $14.56 and a one year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the previous year, the business earned ($0.72) earnings per share. As a group, sell-side analysts expect that Denali Therapeutics Inc. will post -2.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. The Goldman Sachs Group lowered their price target on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Baird R W upgraded shares of Denali Therapeutics to a “strong-buy” rating in a report on Tuesday, January 7th. Robert W. Baird started coverage on shares of Denali Therapeutics in a research note on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 price target on the stock. William Blair reissued an “outperform” rating on shares of Denali Therapeutics in a research report on Wednesday, January 15th. Finally, Jefferies Financial Group boosted their price objective on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.